Research programme: HIV infections therapy - TA Therapeutics

Drug Profile

Research programme: HIV infections therapy - TA Therapeutics

Alternative Names: GRN 665; GRN 951; GRN139951; GRN140665; TAT 0001; TAT 0002; TAT1; TAT2

Latest Information Update: 12 Mar 2010

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Geron Corporation; TA Therapeutics
  • Class Small molecules
  • Mechanism of Action Telomerase activators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical HIV infections

Most Recent Events

  • 12 Mar 2010 Preclinical development is ongoing in USA
  • 12 Nov 2008 In vitro pharmacodynamics data of TAT 2 in HIV infections released by Geron
  • 18 May 2006 Preclinical data from a media release have been added to the Viral Infections pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top